MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway.
For research use only. We do not sell to patients.
| Name | MK256 |
|---|---|
| Iupac Chemical Name | 1-amino-5-bromobenzo[h]isoquinoline-8-carboxylic acid |
| Synonyms | MK256 ; MK 256 ; MK-256 |
| Molecular Formula | C14H9BrN2O2 |
| Molecular Weight | 315.98 |
| Smile | O=C(C1=CC=C2C(C=C(Br)C3=C2C(N)=NC=C3)=C1)O |
| InChiKey | SNTFBMJZDZCZRU-UHFFFAOYSA-N |
| InChi | InChI=1S/C14H9BrN2O2/c15-11-6-8-5-7(14(18)19)1-2-9(8)12-10(11)3-4-17-13(12)16/h1-6H,(H2,16,17)(H,18,19) |
| CAS Number | 2271348-04-8 |
| Related CAS | 2271348-04-8 |
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | Solid powder |
|---|---|
| Purity | ≧98.0% |
| Storage | Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years). |
| Solubility | Soluble in DMSO (DMSO : ≥ 100 mg/mL) |
| Handling | Refer to MSDS |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| HS Code | 2934200090 |
| Targets | CDK8 inhibitor |
|---|---|
| Mechanism | MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway. |
| Cell study | |
| Animal study | |
| Clinical study |